Myriad
Intermountain Gets National Stage, Myriad Adds Tumor Profiling Panel With Combined Test Offering
Premium
Although the logistics still need to be worked out, the partners hope to streamline oncologists' experience ordering tests that can inform patient care.
Myriad Genetics, Intermountain Healthcare Collaborate for Cancer Testing Service
The new service, slated for launch in the second half of 2021, will allow Myriad to expand its cancer tumor profiling services.
Myriad Genetics Quarterly Revenues Decline 21 Percent
Total revenues for the period were $154.6 million, down from $195.1 million but beating the consensus Wall Street estimate.
Fulgent Genetics, Genetron Pace Stock Price Increases as 360Dx Index Rises 10 Percent to Start 2021
Of the 32 companies in the index, 27 firms saw their stock prices increase, while 5 saw their share prices decline.
In Brief This Week: Myriad Genetics, Precipio, LumiraDx, Guardant Health, and More
News items for the in vitro diagnostics industry for the week of Jan. 18, 2021.